FBXW7 Antibody

說(shuō)明書

中文名稱：

FBXW7兔多克隆抗體
貨號(hào)：

CSB-PA822163LA01HU
規(guī)格：

￥440
圖片：
Immunohistochemistry analysis of human kidney tissue using CSB-PA822163LA01HU at dilution of 1:100

Immunocytochemistry analysis of human small intestine tissue using CSB-PA822163LA01HU at dilution of 1:100
其他：

產(chǎn)品詳情
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

產(chǎn)品名稱：

Rabbit anti-Homo sapiens (Human) FBXW7 Polyclonal antibody
Uniprot No.：

Q969H0
基因名：

FBXW7
別名：

FBXW7; FBW7; FBX30; SEL10; F-box/WD repeat-containing protein 7; Archipelago homolog; hAgo; F-box and WD-40 domain-containing protein 7; F-box protein FBX30; SEL-10; hCdc4
宿主：

Rabbit
反應(yīng)種屬：

Human
免疫原：

Recombinant Human F-box/WD repeat-containing protein 7 protein (1-707AA)
免疫原種屬：

Homo sapiens (Human)

標(biāo)記方式：

Non-conjugated

本頁(yè)面中的產(chǎn)品，F(xiàn)BXW7 Antibody (CSB-PA822163LA01HU)，的標(biāo)記方式是Non-conjugated。對(duì)于FBXW7 Antibody，我們還提供其他標(biāo)記。見(jiàn)下表：

標(biāo)記方式	貨號(hào)	產(chǎn)品名稱	應(yīng)用
HRP	CSB-PA822163LB01HU	FBXW7 Antibody, HRP conjugated	ELISA
FITC	CSB-PA822163LC01HU	FBXW7 Antibody, FITC conjugated
Biotin	CSB-PA822163LD01HU	FBXW7 Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA, IHC

推薦稀釋比：

Application	Recommended Dilution
IHC	1:20-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲(chǔ)存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

功能：

Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Recognizes and binds phosphorylated sites/phosphodegrons within target proteins and thereafter bring them to the SCF complex for ubiquitination. Identified substrates include cyclin-E (CCNE1 or CCNE2), DISC1, JUN, MYC, NOTCH1 released notch intracellular domain (NICD), NFE2L1, NOTCH2, MCL1, and probably PSEN1. Acts as a negative regulator of JNK signaling by binding to phosphorylated JUN and promoting its ubiquitination and subsequent degradation. Involved in bone homeostasis and negative regulation of osteoclast differentiation. Regulates the amplitude of the cyclic expression of hepatic core clock genes and genes involved in lipid and glucose metabolism via ubiquitination and proteasomal degradation of their transcriptional repressor NR1D1; CDK1-dependent phosphorylation of NR1D1 is necessary for SCF(FBXW7)-mediated ubiquitination. Also able to promote 'Lys-63'-linked ubiquitination in response to DNA damage. The SCF(FBXW7) complex facilitates double-strand break repair following phosphorylation by ATM: phosphorylation promotes localization to sites of double-strand breaks and 'Lys-63'-linked ubiquitination of phosphorylated XRCC4, enhancing DNA non-homologous end joining.
基因功能參考文獻(xiàn)：
1. Multivalent Interactions with Fbw7 and Pin1 Facilitate Recognition of c-Jun by the Fbw7. PMID: 29225075
2. FBXW7 is critical for RIG-I stabilization during antiviral responses. PMID: 28287082
3. Expression of miR-223 is negatively correlated with F-box and WD repeat domain-containing 7 (FBXW7) expression in cells and tissues. PMID: 29701752
4. FBXW7 conduction of tumour suppression was partly through degrading Snai1 directly for ubiquitylating regulation in NSCLC. PMID: 30094882
5. Data showed that both chemo and radiation sensitivity increased in TE-8 and KYSE140 cells overexpressing FBXW7 compared with mock cells because of the degradation of the anti-apoptotic protein MCL1. PMID: 30098297
6. Fbw7 mutations shifted cellular metabolism toward oxidative phosphorylation and caused context-specific metabolic vulnerabilities. PMID: 29735700
7. TINCR suppressed proliferation and invasion through regulating miR-544a/FBXW7 axis in lung cancer. PMID: 29324317
8. Low FBXW7 expression is associated with non-small cell lung cancer. PMID: 28656290
9. we identified F-box and WD repeat domain-containing 7 (FBXW7) protein as a direct functional target of miR-25 in esophageal squamous cell carcinoma (ESCC). In conclusion, the present study supports the potential of miR-25 as a prognostic predictor with its high expression in cancer tissues and its association with tumor progression by targeting FBXW7 in ESCC PMID: 29048664
10. FBXW7 was significantly downregulated in renal cell carcinoma cell lines. Upregulation of FBXW7 in 786-O and ACHN cell lines significantly inhibited cell migration, invasion and EMT. PMID: 29097832
11. FBXW7 missense mutation is associated with metastatic colorectal adenocarcinoma. PMID: 28424412
12. miR-92b-3p inhibition prevented colorectal cancer proliferation, invasion, and migration by upregulating FBXW7, which might suggest the potential role of miR-92b-3p in colorectal carcinogenesis and metastasis. PMID: 29638162
13. FBXW7 is markedly downregulated in the liver of obese subjects. A functional low-frequency human FBXW7 coding variant (p.Ala204Thr) is associated with elevated blood glucose and T2DM risk in a Chinese population. Mechanistically, FBXW7 directly binds to hepatokine fetuin-A to induce its ubiquitination and subsequent proteasomal degradation, comprising an important mechanism maintaining glucose homeostasis. PMID: 29475832
14. Our findings suggest FBW7 mutational status and Mcl-1 stability as key determinants of response to Hsp90 inhibitors, which provides a rationale for using FBW7 genotype for potential patient stratification, and for drug combinations with Hsp90 inhibitors that can effectively overcome Mcl-1-mediated resistance. PMID: 28619760
15. a cancer stem cell-specific FBXW7-regulatory mechanism is strongly associated with resistance to chemotherapeutic agents. PMID: 28699179
16. FBW7 promoted gemcitabine sensitivity via upregulation of equilibrative nucleoside transporter 1 (ENT1) at the protein level rather than the transcriptional level. PMID: 28765935
17. FBW7 overexpression downregulated Aurora B, Mcl1 and Notch1 levels. PMID: 29427543
18. FBXW7 was a downstream target of miR-367 and CASC2 prohibited epithelial-to-mesenchymal transition progression and subsequently exerted its anti-metastatic effects via CASC2/miR-367/FBXW7 axis in hepatocellular carcinoma cells. PMID: 28716020
19. FBW7 cooperated with gamma-catenin to inhibit G2/M cell cycle transition and cell proliferation. PMID: 29408378
20. We also propose a model for the stabilization mechanism in which binding to Aurora-A alters how N-Myc interacts with SCF(FbxW7) to disfavor the generation of Lys48-linked polyubiquitin chains PMID: 27837025
21. We find that both primary and recurrent Squamous cell carcinoma of the anal canal (ASCC) tumors harbor mutations in genes, such as PIK3CA and FBXW7, that are also mutated in other HPV-associated cancers. Overall mutational burden was not significantly different in pre- versus post-CRT tumors, and several examples of shared clonal driver mutations were identified PMID: 27852700
22. We have identified low FBXW7 expression as a potential powerful marker of poor prognosis in patients with gastric adenocarcinoma. Furthermore, in view of the different chemotherapeutics outcomes found in this large database study, FBXW7 may serve as an important predictor in chemotherapeutic responses. PMID: 28464881
23. Fbxw7 haploinsufficiency increased the risk of gastric carcinogenesis induced by MNU, which is associated with the accumulation of DNA damage as well as c-Myc oncoprotein. PMID: 28422719
24. EglN2 might act as an FBW7 ubiquitin ligase substrate contributing to the progression of triple negative breast cancer. PMID: 28036276
25. FAM83D knockdown up-regulated the protein expression level of F-box and WD repeat domain-containing 7 (FBXW7), but diminished the Notch1 protein expression level. PMID: 28407575
26. Thus, our study uncovers a novel regulatory mechanism underlying which KLF10 stability and its biological function are mediated by FBW7. PMID: 29198712
27. Results found it showed reduced expression in diffuse large B-cell lymphoma (DLBCL), which was associated with a poor outcome. Fbw7 expression promotes apoptosis in DLBCL cell lines. Furthermore, the study demonstrated that Fbw7 targets Stat3 and especially activated Stat3 for ubiquitylation to regulate its stability. PMID: 28069035
28. Data suggest that FBXW7, MCL1 and PLK1 may be relevant predictive markers of tumor progression and response to paclitaxel treatment. PMID: 27409838
29. FBW7 serves as a negative regulator of glucose metabolism through regulation of the c-Myc/TXNIP axis in pancreatic cancer. PMID: 26983463
30. increased expression of activated NOTCH1 was found in NOTCH1/FBXW7 hotspot exon-mutated cases. Study suggests that NOTCH1/FBXW7 hotspot-mutated T-ALL cases had better response to ALL BFM-95 protocol. PMID: 29200162
31. Study identify SCF-FBW7 as a ubiquitin E3 ligase that regulates the cellular FAAP20 levels and Fanconi anemia (FA) pathway. Deregulation of the GSK3beta- and FBW7-dependent FAAP20 degradation leads to a defect in the FA pathway, establishing a direct link between FBW7 and DNA repair. PMID: 27232758
32. HRAS mutations were more common in epithelial-myoepithelial carcinomas (EMCAs) with intact PLAG1 and HMGA2. Most EMCAs arose ex pleomorphic adenoma (PA)and the genetic profile of EMCA varies with the absence or presence of preexisting PA and its cytogenetic signature. Progression to higher grade EMCA with intact PLAG1 and HMGA2 correlates with the presence of TP53, FBXW7 mutations, or SMARCB1 deletion. PMID: 29135520
33. Data indicate the SCF(Fbxw7)-independent regulatory mechanism centred on the highly conserved lysine-52 (K52) within MYC Box I. PMID: 28806398
34. Results identified FBXW7 as a functional target of miR-155-3p and demonstrated an involvement of FBXW7 in the effects of increased miR-155-3p on promoting clone formation and proliferation of hepatocellular carcinoma. PMID: 27306418
35. FBXW7alpha inhibits breast cancer cells survival by promoting GATA3 degradation/destabilizing GATA3. PMID: 28722108
36. Loss of FBW7 expression is associated with breast cancer. PMID: 28760857
37. FBXW7 could be a potential biomarker for predicting not only the clinical response to chemoradiotherapy but also overall survival in patients with oral squamous cell carcinoma PMID: 29072128
38. Our results reveal a new mechanism of ZNF322A oncoprotein destruction regulated by the CK1delta/GSK3beta/FBXW7a axis. Deregulation of this signaling axis results in ZNF322A overexpression and promotes cancer progression PMID: 28581525
39. Low FBXW7 expression is associated with pancreatic cancer. PMID: 28423622
40. siRNA interference of FBXW7 reversed the inhibitory effect of MAGEA1 on migration and proliferation of MCF-7 and MDA-MB-231 cells. PMID: 28459460
41. Endogenous circRNA encodes a functional protein in human cells, and circ-FBXW7 and FBXW7-185aa have potential prognostic implications in brain cancer. PMID: 28903484
42. Dual FBXW7-GAK inhibition increases multipolar mitoses. PMID: 28829765
43. EXT1, a gene not previously linked to acute lymphoblastic leukemia via mutations, is a common interactor of NOTCH1 and FBXW7 regulating the NOTCH pathway in an FBXW7-dependend manner. PMID: 27229929
44. C-MYC and FBXW7 affect Adult T-cell Leukemia/Lymphoma proliferation and progression, and low FBXW7 may increase C-MYC expression. C-MYC was a critical prognostic factor in Adult T-cell Leukemia/Lymphoma patients. PMID: 28498285
45. The findings reveal a PLK1-Fbw7-Myc signaling circuit that underlies tumorigenesis and validate PLK1 inhibitors, alone or with Bcl2 antagonists, as potential effective therapeutics for MYC-overexpressing cancers. PMID: 27773673
46. Findings demonstrate that Fbw7 targets CDX2 for ubiquitin-mediated proteasome degradation in a GSK3b-dependent manner where GSK3b presumably phosphorylates CDX2 within the two potential phosphodegron motifs. PMID: 27470268
47. Plk2 represents an independent prognostic marker and regulates tumor growth and apoptosis by targeting Fbxw7/Cyclin E pathway in colorectal carcinoma. PMID: 27423313
48. Here, we show that the SCFFBW7alpha ubiquitin ligase targets SOX9 for proteasomal degradation and provide experimental evidence of a role for FBW7 in modulating medulloblastoma malignancy and cisplatin resistance by controlling SOX9 proteolysis. PMID: 27625374
49. The authors show that STYX binds to the F-box domain of FBXW7 and disables its recruitment into the SCF ubiquitin ligase complex. PMID: 28007894
50. In colorectal cancers, mutations in the FBXW7 gene were more common in the younger cohort (27.5% vs 9.7%; P = .0022) as were mutations in the proofreading domain of polymerase epsilon catalytic subunit (POLE) (9.8% vs 1%; P = .0048). PMID: 27244218
顯示更多

收起更多
亞細(xì)胞定位：

[Isoform 1]: Nucleus, nucleoplasm. Chromosome.; [Isoform 2]: Cytoplasm.; [Isoform 3]: Nucleus, nucleolus.
組織特異性：

[Isoform 1]: Widely expressed.; [Isoform 3]: Expressed in brain.
數(shù)據(jù)庫(kù)鏈接：

HGNC: 16712

OMIM: 606278

KEGG: hsa:55294

STRING: 9606.ENSP00000281708

UniGene: Hs.561245

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human